Eisai gives up on sibutramine in Japan
This article was originally published in Scrip
Executive Summary
Eisai has withdrawn a Japanese approval application for the obesity drug sibutramine, following originator Abbott's decision to pull the product from several major markets.
You may also be interested in...
Daiichi’s EZH Contender Moves Ahead In Leukemia/Lymphoma
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports